D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|September 27, 2011
The 2011 European Multidisciplinary Cancer Congress Slideshow
Author(s)Onclive Team
Pictures from The 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden
Advertisement
Pictures from the 16th ECCO, 36th ESMO, 30th ESTRO Congresses that combined to form the 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden, September 23-27. Pictures include images from the conference and Stockholm, Sweden.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5